A range of
antitumor agents for
cancer treatment is available; however, they show low specificity, which often limit their use. Recently, we have reported the preparation of
folate-coated long-circulating and pH-sensitive
liposomes (SpHL-
folate-PTX) loaded with
paclitaxel (PTX), an effective drug for the treatment of solid
tumors, including
breast cancer. The purpose of this study was to prepare and characterize SpHL-PTX and SpHL-
folate-PTX radiolabeled with technetium-99m (99mTc). Biodistribution studies and scintigraphic images were performed after
intravenous administration of 99mTc-PTX, 99mTc-SpHL-PTX and 99mTc-SpHL-folate-PTX into healthy and
tumor-bearing mice. High radiochemical purity (>98%) and in vitro stability (>90%) were achieved for both
liposome formulations. The pharmacokinetic properties of 99mTc-SpHL-DTPA-PTX and 99mTc-SpHL-folate-DTPA-PTX decreased in a monophasic manner showing half-life of 400.1 and 541.8min, respectively. Scintigraphic images and biodistribution studies showed a significant uptake in liver, spleen and kidneys, demonstrating these routes as way for excretion. At 8h post-injection, the liposomal
tumor uptake was higher than 99mTc-PTX. Interesting, 4h after administration, the
liposome folate coated showed higher
tumor-to-muscle ratio than 99mTc-SpHL-DTPA-PTX and 99mTc-PTX. In conclusion, the liposomal systems, showed high
tumor uptake by scintigraphic images, especially the 99mTc-SpHL-folate-DTPA-PTX that showed a sustained and higher
tumor-to-muscle ratio than non-functionalized
liposome, which indicate its feasibility as a PTX delivery system to
folate positive
tumors.